Skip to main content
. Author manuscript; available in PMC: 2022 Sep 14.
Published in final edited form as: Nat Cardiovasc Res. 2022 Mar 14;1(3):211–222. doi: 10.1038/s44161-022-00032-w

Figure 4.

Figure 4.

Potential contributions of innate immunity to the pathogenesis of cardiometabolic HFpEF. Depicted is a working model in which cardiometabolic risk factors, including visceral adiposity and hypertension, fuel immunometabolic mobilization of innate immune cell subsets. This immune cell mobilization, in turn, activates intercellular crosstalk that also regulates myocardial metabolic pathways.

HSPC: hematopoietic stem/progenitor cell

Mϕ: macrophages

IL-1β: interleukin 1β